Product image of Maraviroc Amarox (Maraviroc) supplied by GNH India

Maraviroc Amarox

Active Ingredient:
Maraviroc
Origin:
EU

Maraviroc Amarox (Maraviroc)

Maraviroc, the active ingredient in Maraviroc Amarox, is a CCR5 antagonist presented as an oral tablet for oral use. It is indicated for the treatment of CCR5‑tropic HIV‑1 infection in adults, typically as part of combination antiretroviral therapy to suppress viral replication and improve immune function.

GNH India supplies Maraviroc Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Manufacturer / TM Owner

Amarox Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Maraviroc is used to treat infections that rely on the CCR5 co‑receptor pathway in HIV‑1 disease.
  • CCR5‑tropic HIV‑1 infection (treatment‑naïve patients): Used in combination regimens to achieve viral suppression.
  • CCR5‑tropic HIV‑1 infection (treatment‑experienced patients): Added to existing therapy when resistance to other agents is present.
  • CCR5‑tropic HIV‑1 infection (pre‑exposure prophylaxis research): Investigated as part of combination strategies to prevent acquisition of HIV.

How It Works

  • Maraviroc selectively binds to the CCR5 co‑receptor on the surface of CD4+ T cells, preventing the HIV‑1 envelope glycoprotein gp120 from attaching. By blocking this entry pathway, the drug inhibits viral fusion and entry into host cells, thereby reducing viral replication and allowing immune recovery when used with other antiretrovirals.

Side Effects

Maraviroc may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Headache: Mild to moderate intensity, often transient.
  • Nausea: May occur with or without vomiting.
  • Diarrhea: Usually self‑limiting.
  • Fatigue: Generalized tiredness reported by some patients.
  • Rash: Mild skin eruptions.
  • Dizziness: May affect balance.

Serious or Rare Side Effects

  • Severe liver injury: Elevated transaminases or hepatitis.
  • Allergic reactions: Anaphylaxis, angioedema, or severe skin reactions such as Stevens‑Johnson syndrome.
  • Depression or mood changes: Monitor mental health.
  • Cardiovascular events: Rare cases of myocardial infarction.
  • Immune reconstitution syndrome: Worsening of opportunistic infections after immune recovery.

Precautions & Warnings

  • Before initiating Maraviroc, clinicians should consider several safety measures.
  • Liver function monitoring: Perform baseline and periodic liver enzyme tests.
  • Cardiovascular assessment: Evaluate history of heart disease before initiation.
  • Resistance testing: Confirm CCR5‑tropic virus prior to therapy.
  • Hypersensitivity reaction: Discontinue if rash, swelling, or anaphylaxis occurs.
  • Pregnancy and breastfeeding: Use only if potential benefit justifies potential risk.
  • Store at ambient temperature below 25 °C: Keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Maraviroc interacts with several drug classes; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase maraviroc plasma levels and toxicity.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce maraviroc efficacy.
  • Protease inhibitors boosted with ritonavir: Can markedly elevate maraviroc concentrations.

Moderate Interactions (Monitor Closely)

  • Other antiretrovirals (e.g., efavirenz): May alter maraviroc levels.
  • Antacids containing aluminum or magnesium: May affect oral absorption.
  • Warfarin: Monitor INR for potential anticoagulant effect changes.

Frequently Asked Questions

Maraviroc Amarox is prescribed for the treatment of CCR5‑tropic HIV‑1 infection. It is used as part of combination antiretroviral therapy to lower viral load and help restore immune function in adults living with HIV.

Maraviroc blocks the CCR5 co‑receptor on CD4+ T cells, preventing the HIV‑1 virus from binding and entering the cell. By inhibiting this entry step, the drug reduces viral replication and supports the effectiveness of other antiretroviral agents.

The dose of Maraviroc Amarox is determined by the prescribing clinician based on the patient’s clinical status, viral resistance profile, and concomitant medications. Standard dosing guidelines exist, but the final regimen must be individualized by a qualified healthcare professional.

The safety of Maraviroc in pregnancy and lactation has not been definitively established. It should be used only if the potential benefits outweigh the possible risks to the fetus or infant, and the decision should be made in consultation with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and the necessary import documentation.

Maraviroc belongs to the CCR5 antagonist class, targeting a specific viral entry pathway, whereas most other antiretrovirals inhibit reverse transcription, integration, or protease activity. This distinct mechanism makes it valuable for patients with resistance to other classes, but it is effective only against CCR5‑tropic strains of HIV.

Maraviroc Amarox should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not freeze the tablets, and keep them out of reach of children.

Maraviroc Amarox is taken orally, usually with food to improve absorption. The tablets are swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe liver injury, allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, depression or mood changes, cardiovascular events, and immune reconstitution inflammatory syndrome. Patients should be monitored closely for any of these events, especially during the early phases of therapy.

Maraviroc Amarox should not be used in patients with known hypersensitivity to maraviroc or any of its excipients, and it is ineffective in individuals infected with HIV strains that use the CXCR4 co‑receptor instead of CCR5. Caution is also advised for patients with significant liver disease or uncontrolled cardiovascular conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Maraviroc

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT